Drug and Therapeutics Bulletin 2005;43:85-88; doi:10.1136/dtb.2005.431185
Copyright © 2005 by the BMJ Publishing Group Ltd.
Leukotriene receptor antagonists - an update
Relevant BNF sections: 3.1, 3.3.2
Montelukast (Singulair - MSD) and zafirlukast (Accolate - AstraZeneca) are oral leukotriene receptor antagonists, licensed for the treatment of patients with asthma. In 1998, soon after their launch, we concluded that there was insufficient evidence to clearly define their place in treatment.1 Here, we reconsider their role in adults and children with asthma in the light of more recent evidence.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
-
Respiratory system
-
Endocrine system
-
Obstetrics, gynaecology and fertility
-
Malignant disease and immunosuppression
-
Haematology (drugs and medicines)
Bookmark with
Register for email alerts
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Coming soon!
The DTB archive back to 1962, volume 1, issue 1 will soon be available.
